200,000 Shares in TELA Bio, Inc. $TELA Purchased by Paradigm Capital Management Inc. NY

Key Points

• Paradigm Capital Management Inc. acquired 200,000 shares of TELA Bio, Inc., valued at approximately $244,000, representing a 0.51% ownership stake.
• Analysts have downgraded TELA Bio's rating from "hold" to "sell", while the average rating remains a "Moderate Buy" with a target price of $4.50.
• Despite a revenue report of $20.20 million in the last quarter, TELA Bio missed the consensus estimate, with a reported EPS of ($0.22).

Paradigm Capital Management Inc. NY acquired a new stake in shares of TELA Bio, Inc. (NASDAQ:TELA - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 200,000 shares of the company's stock, valued at approximately $244,000. Paradigm Capital Management Inc. NY owned 0.51% of TELA Bio as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Jane Street Group LLC raised its position in TELA Bio by 30.5% during the 4th quarter. Jane Street Group LLC now owns 30,705 shares of the company's stock valued at $93,000 after purchasing an additional 7,174 shares in the last quarter. Cubist Systematic Strategies LLC grew its stake in TELA Bio by 95.3% during the 4th quarter. Cubist Systematic Strategies LLC now owns 31,313 shares of the company's stock worth $95,000 after buying an additional 15,283 shares during the last quarter. Northern Trust Corp grew its stake in TELA Bio by 50.6% during the 4th quarter. Northern Trust Corp now owns 47,181 shares of the company's stock worth $142,000 after buying an additional 15,856 shares during the last quarter. Velan Capital Investment Management LP purchased a new position in TELA Bio during the 1st quarter worth $912,000. Finally, Mink Brook Asset Management LLC purchased a new position in TELA Bio during the 4th quarter worth $1,078,000. 94.35% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded TELA Bio from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, TELA Bio presently has an average rating of "Moderate Buy" and a consensus price target of $4.50.

TELA Bio Stock Performance

Shares of TELA stock traded down $0.06 on Thursday, hitting $1.59. The company had a trading volume of 66,693 shares, compared to its average volume of 171,267. The firm has a market cap of $62.99 million, a P/E ratio of -1.42 and a beta of 0.84. The company has a 50-day moving average price of $1.85 and a 200-day moving average price of $1.67. The company has a quick ratio of 2.59, a current ratio of 3.19 and a debt-to-equity ratio of 4.14. TELA Bio, Inc. has a twelve month low of $0.86 and a twelve month high of $3.26.

TELA Bio (NASDAQ:TELA - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.04). The company had revenue of $20.20 million during the quarter, compared to analyst estimates of $20.67 million. TELA Bio had a negative net margin of 54.12% and a negative return on equity of 329.48%. TELA Bio has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that TELA Bio, Inc. will post -1.37 earnings per share for the current fiscal year.

TELA Bio Profile

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.